News
ICPT
19.00
0.00%
0.00
Weekly Report: what happened at ICPT last week (0226-0301)?
Weekly Report · 03/04 09:25
Weekly Report: what happened at ICPT last week (0219-0223)?
Weekly Report · 02/26 09:27
Weekly Report: what happened at ICPT last week (0212-0216)?
Weekly Report · 02/19 09:27
CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst
Gilead Sciences Inc agreed to acquire CymaBay Therapeutics Inc for $32.50 per share in cash. Gilead's seladelpar for liver disease is a low-risk acquisition, says Baird. The drug has the potential to achieve blockbuster peak annual sales of $800 million.
Benzinga · 02/13 19:05
Weekly Report: what happened at ICPT last week (0205-0209)?
Weekly Report · 02/12 09:25
Weekly Report: what happened at ICPT last week (0129-0202)?
Weekly Report · 02/05 09:27
Weekly Report: what happened at ICPT last week (0122-0126)?
Weekly Report · 01/29 09:25
Weekly Report: what happened at ICPT last week (0115-0119)?
Weekly Report · 01/22 09:26
Weekly Report: what happened at ICPT last week (0108-0112)?
Weekly Report · 01/15 09:25
Weekly Report: what happened at ICPT last week (0101-0105)?
Weekly Report · 01/08 09:26
Madrigal Pharmaceuticals: A Deeper Look At A Looming NASH Play
Madrigal Pharmaceuticals, Inc. Stock has rallied 70% since late October due to a decrease in competitive concerns and a large secondary offering. The company's candidate resmetirom is expected to be the first approved therapy for NASH in March 2024. The NASH market is estimated to reach $20 billion by 2030.
Seeking Alpha · 01/02 16:12
Weekly Report: what happened at ICPT last week (1225-1229)?
Weekly Report · 01/01 09:25
Weekly Report: what happened at ICPT last week (1218-1222)?
Weekly Report · 12/25/2023 09:27
Weekly Report: what happened at ICPT last week (1211-1215)?
Weekly Report · 12/18/2023 09:28
Weekly Report: what happened at ICPT last week (1204-1208)?
Weekly Report · 12/11/2023 09:28
Weekly Report: what happened at ICPT last week (1127-1201)?
Weekly Report · 12/04/2023 09:27
Tharimmune stock rockets 46% on positive Phase 1 data for PBC drug
Tharimmune stock rockets 46% on positive phase 1 data for its drug candidate th104 in the treatment of chronic pruritis in patients with primary biliary cholangitis. Tharimmune shares opened at $2.93 and closed at $4.79.
Seeking Alpha · 11/27/2023 15:34
Weekly Report: what happened at ICPT last week (1120-1124)?
Weekly Report · 11/27/2023 09:26
Weekly Report: what happened at ICPT last week (1113-1117)?
Weekly Report · 11/20/2023 09:26
Circling Back On CymaBay Therapeutics
Cymabay therapeutics is a clinical stage biopharma company focused on developing therapies for liver and chronic diseases. The company's primary product candidate, seladelpar, has shown positive results in treating primary biliary cholangitis. The stock has rallied 80% since we last looked at the company six months ago. Analyst firms are positive on the company's prospects despite a recent rally in the stock. Insiders have sold a decent amount of shares in recent months.
Seeking Alpha · 11/19/2023 14:52
More
Webull provides a variety of real-time ICPT stock news. You can receive the latest news about Intercept Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ICPT
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other Product Candidates. The Company’s marketed product, Ocaliva, is a farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. The Company is evaluating tolerability of OCA in combination with bezafibrate in patients with PBC in a Phase II study outside of the United States. Its other compounds are in early stages of research and development pipeline including INT-787 compound, an FXR agonist is in a Phase IIa clinical trial.